10.30699/jambs.28.129.183 Background & Objective: The mechanism of analgesic and anxiolytic activity of resveratrol in neuropathic pain conditions remains obscure. The present study was conducted to examine whether the analgesic and anxiolytic activities of resveratrol are associated with α1-and α2-adrenoceptors of the anterior cingulate cortex (ACC), which is a key area of the cortex in the pain process, following neuropathic pain in rats. Materials & Methods: Neuropathic pain was created by chronic constriction injury (CCI) of the sciatic nerve. Male Wistar rats were assigned to the sham, CCI, CCI+resveratrol (40 μg/5 μL), CCI+resveratrol+prazosin (α1-adrenoceptor antagonist, 30 μg/5 μL), and CCI+resveratrol-Yohimbine (α2-adrenoceptor antagonist, 30 μg/5 μL) groups. The rats received intra-ACC injection of the drug on the day of CCI and for 6 days post-CCI on a daily basis. Cold allodynia (using acetone test) and anxiety (using elevated plus maze, EPM) were examined on days 2, 4, and 6 following CCI. Results: CCI model significantly increased cold allodynia and anxiety. Resveratrol significantly decreased cold allodynia. Prazosin induced no significant changes in allodynia as compared with the CCI+resveratrol treated group. But the animals in this group had no significant difference from the day before the surgery or compared with the sham group. Prazosin significantly decreased entries into open arms. Additionally, yohimbine significantly increased cold allodynia as compared with the CCI+resveratrol treated group. However, it induced no significant changes in the EPM parameters. Our findings also demonstrated a significant correlation between allodynia and anxiety in CCI rats. Conclusion: It is suggested that the mechanism of analgesic and anxiolytic activities of resveratrol in the ACC of rats is different, and is mediated through α2and α1-adrenoceptors, respectively.

suppressed cold allodynia and anxiety through α2-adrenoceptors in the anterior cingulate cortex following chronic constriction injury of sciatic nerve in rats.

The propagation of the new coronavirus, COVID 19, is still a major priority for many countries around the world. Because of the lack of effective certain antiviral therapy for COVID 19. Special medicinal protocols are needed in medical centers to reduce the mortality rate. Methods: Due to constant change of national pharmacotherapy protocols for COVID-19 patients, this study compares the outcomes of three specific pharmacotherapy regimens (Table 1) and the combination of all 3 regimens for management of 614 COVID-19 patients hospitalized in Baqiyatallah hospital in Tehran, this hospital became a referral centers for receiving COVID 19 patients in Iran. Results: The more reliable result of treatments belongs to regimen 3 which indicated 98.26% recovered patients and 1.15% mortality rate and the lowest period of hospitalization with 4.4±0.21 days' duration. Conclusion: It seems that regimen 3 (with a special combination of antiviral and Azithromycin ant anti-inflammatory drugs) had the best result in improving patients with COVID 19 and this result has not conflict with the comorbidity status of patients.